Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer
Miki Gondo1, Tsutomu Sakai1, Hiroshi Tsuneoka1, Chihiro Kanehira2
1Department of Ophthalmology, Jikei University School of Medicine, 2Division of Radiology, Jikei University School of Medicine, Tokyo, Japan
Background: The evaluation of intravitreal bevacizumab treatment for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer.
Case report: A patient with radiation maculopathy and papillopathy was treated with intravitreal bevacizumab (1.25 mg). Main outcome measures included fundus photography, angiography, and optical coherence tomography (OCT). Two weeks after intravitreal bevacizumab, visual acuity improved from 0.4 to 1.2. Fundus examination revealed decreased disc swelling, peripapillary hemorrhage, and macular edema. OCT demonstrated complete resolution of serous retinal detachment. At the 12-month follow-up, there was no exudation recurrence. No ocular or systemic side effects were observed.
Conclusion: Intravitreal bevacizumab can be used to treat radiation maculopathy and papillopathy. Antivascular endothelial growth factor therapy may decrease tissue injury associated with radiation vasculopathy.
Keywords: bevacizumab, radiation, maculopathy, papillopathy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]